Rural Health Clinical Congress Fall 2023

CME/CE INFORMATION

Rural Health Clinical Congress Fall 2023

Saturday, November 18, 2023 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT

HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it.
Step 2: Complete Evaluation(s)
Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
Step 3: View and Print Certificate(s)
After you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.

Advances in the Treatment of Food Allergy: Optimizing Outcomes
in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

This session is supported by an educational grant from Genentech, a member of the Roche Group.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.25 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

Assess the burden and impact of food allergies on the quality of life of patients
Compare the benefits and limitations of current and new/emerging therapies for the treatment of food allergies
Assess the safety and efficacy of novel biologic therapies for the prevention and management of food allergies
Utilize strategies to improve care access and overcome existing barriers for the management of patients with food allergies residing in rural and underserved communities

FACULTY
Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine, Northwestern University Feinberg School of Medicine
Clinical Attending, Ann & Robert H. Lurie Children’s Hospital of Chicago
Founding Director, Center for Food Allergy & Asthma Research (CFAAR)
Chicago, IL

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Ruchi S. Gupta, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for Aimmune LLC, Allergenis LLC, Genentech, Inc., and Novartis Pharmaceuticals Corporation; contracted research for Genentech, Inc., and Novartis Pharmaceuticals Corporation.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Chronic Rhinosinusitis With Nasal Polyps: A Patient-Centered Approach
to Improving Care and Outcomes in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Genentech, a member of the Roche Group; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Recognize the key clinical features of chronic rhinosinusitis with nasal polyps (CRSwNP) and the potential impact on patients’ quality of life
Summarize the efficacy and safety data of new and emerging biologic therapy for CRSwNP
Identify appropriate patients with CRSwNP who may be eligible for biologic therapy
Utilize an individualized, team-based approach for CRSwNP to improve access to care and treatment in rural and underserved areas

FACULTY

Stella E. Lee, MD
Section Chief, Rhinology
Director, Brigham Sinus Center
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Stella E. Lee, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., Genzyme, GSK, Lyra Therapeutics, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals, Inc.; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., Novartis Pharmaceuticals Corporation, GSK, Lyra Therapeutics, Sanofi and Regeneron Pharmaceuticals, Inc., Genzyme, OptiNose, Inc.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Keeping an Eye on Equity: Improving Care of Age-Related Macular Degeneration
and Diabetic Retinopathy in Rural and Underserved Areas

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Implement strategies for improving screening and early treatment of age-related macular degeneration (AMD) and diabetic retinopathy (DR)
Evaluate the safety and efficacy of available treatment options for AMD and DR
Develop strategies to improve early treatment and patient care using shared decision-making and collaboration for patients with retinal disease in rural and underserved areas

FACULTY
Yasha S. Modi, MD
Associate Professor of Ophthalmology
NYU Grossman School of Medicine
Director, Tele-Retina
New York, NY

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Yasha S. Modi, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Alimera Sciences, Inc., Alcon, Apellis Pharmaceuticals, Astellas Pharma, Inc., Bausch + Lomb, Dutch Ophthalmic Research Center, EyePoint Pharmaceuticals, Genentech, Inc., Notal Vision, Thea Pharma, Inc., Regeneron Pharmaceuticals, Inc., and ZEISS Group.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Primary Care Management of Vasomotor Symptoms Associated With Menopause: Improving Care in Rural and Underserved Settings

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Identify risk factors and racial and ethnic differences that impact the timing of menopause, as well as the duration and frequency of vasomotor symptoms associated with menopause
Apply current recommendations for menopausal hormone therapy, including factors to consider when determining whether it is an appropriate treatment option for certain patient groups
Summarize the latest clinical trial data on the efficacy and safety of novel nonhormonal treatment options for vasomotor symptoms associated with menopause
Utilize strategies for improving menopausal care and management in the rural primary care setting

FACULTY
Hugh S. Taylor, MD
Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences
Professor of Molecular, Cellular, and Developmental Biology
Chair of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine
Chief of Obstetrics and Gynecology, Yale-New Haven Hospital
New Haven, CT

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Hugh S. Taylor, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Organon & Co.; institutional grant/research support from AbbVie, Inc.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Improving Recognition and Treatment of Hyperkalemia
in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Identify patients with or at risk for hyperkalemia based on the presence of risk factors
Evaluate the efficacy and safety of new treatments for hyperkalemia
Develop a treatment plan for patients with hyperkalemia based on the latest guideline recommendations, clinical evidence, and patient characteristics
Employ a multidisciplinary team-based approach to improve the management of hyperkalemia in rural and underserved areas

FACULTY
Matthew R. Weir, MD
Professor and Director, Division of Nephrology
University of Maryland School of Medicine
Attending Physician
University of Maryland Hospital
Baltimore, MD

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Matthew R. Weir, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Bayer Pharmaceuticals, CareDx, CSL Vifor, Novo Nordisk, and Boehringer Ingelheim.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

System checker: Must meet all requirements of BroadcastMed Live Events Platform
Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.